Portfolio company Orna Therapeutics agreed to be acquired by Eli Lilly for up to $2.4B to advance in vivo CAR-T cell therapies.
Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body
Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Their technology focuses on engineered circular RNA and lipid nanoparticle delivery systems, aiming to transform patient care across oncology, autoimmune, infectious, and genetic diseases.